Latest Content

Patients with fatty liver disease are significantly more likely to develop kidney stones, a national study found.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

A targeted therapy combination achieved complete remission in a CAR-positive PTCL patient post-CAR T-cell therapy for multiple myeloma.

LAG-3 expression appears to be significantly elevated in patients with small cell lung cancer (SCLC).

Health care workers face significant financial hardships, including food insecurity and housing instability, impacting retention and patient care quality.

Ken Cohen, MD, FACP, discusses how clinicians can support patients after a cognitive screening to identify meaningful next steps.

COVID-19–related work absences remain elevated post pandemic, especially in high-exposure jobs, highlighting lasting labor market impacts.

Meta-analyses presented at the CHEST 2025 Annual Meeting find that combinations that include amivantamab and nivolumab improved overall and progression-free survival in non–small cell lung cancer (NSCLC).